Research
T cell redirection in high-risk smouldering multiple myeloma: can deep responses prevent progression to multiple myeloma?
Nature · By María-Victoria Mateos ·
The Brief
- A randomized phase II trial called ImmunoPRISM tested teclistamab in high-risk smouldering multiple myeloma.
- The trial showed encouraging efficacy for the BCMA-targeted bispecific T cell engager teclistamab.
- The source reports the study in Nature Reviews Clinical Oncology, published online 10 November 2026.
Why it matters
It offers early evidence that T cell redirection therapy may produce deep responses in a precursor stage of myeloma, which could inform whether treatment should start before symptomatic disease develops.
Who’s affected
- clinicians and researchers in haematologic oncology
- patients with high-risk smouldering multiple myeloma
- #multiple myeloma
- #t cell engager
- #teclistamab
- #smouldering myeloma
- #immunotherapy
Nature Reviews Clinical Oncology, Published online: 10 November 2026; doi:10.1038/s41571-026-01230-2 The randomized phase II ImmunoPRISM trial has shown encouraging efficacy of the B cell maturation antigen-targeted bispecific T cell engager teclistamab in high-risk smouldering…
Timeline
Results of the ImmunoPRISM trial published online in Nature Reviews Clinical Oncology
nature.com
T cell redirection in high-risk smouldering multiple myeloma: can deep responses prevent progression to multiple myeloma?